Relationship between age-related serum concentrations of TGF-β1 and TGF-β2 and those of osteoprotegerin and leptin in native Chinese women

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 63-69

  Zhang, Na ^a,b   Wu, Xi Yu ^a   Wu, Xian Ping ^a   Fu, Xiao Hua ^b   Du, Xiao Yong ^b   Xie, Hui ^a   Peng, Yi Qun ^a   Luo, Xiang Hang ^a   Liao, Er Yuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Leptin; Osteoprotegerin; Serum concentrations; TGF 1; TGF 2

Indexed keywords

LEPTIN; OSTEOPROTEGERIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHINESE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HORMONE BLOOD LEVEL; HUMAN; MENOPAUSE; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CHINA; FEMALE; HUMANS; LEPTIN; MENOPAUSE; MIDDLE AGED; OSTEOPROTEGERIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 64849099567     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.01.021     Document Type: Article

References (56)

1. Janssens K., ten Dijke P., Janssens S., and Van Hul W. Transforming growth factor-beta 1 to the bone. Endocr Rev 26 (2005) 743-774
2. Erlebacher A., and Derynck R. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132 (1996) 195-210
3. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
4. Elefteriou F., Takeda S., Ebihara K., et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101 (2004) 3258-3263
5. Fuller K., Lean J.M., Bayley K.E., Wani M.R., and Chambers T.J. A role for TGF-β1 in osteoclast differentiation and survival. J Cell Sci 113 (2000) 2445-2453
6. Bonewald L.F., and Mundy G.R. Role of transforming growth factor-beta in bone remodeling. Clin Orthop 250 (1990) 261-276
7. Pfeilschifter J., D'Souza S.M., and Mundy G.R. Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology 121 (1987) 212-218
8. Chenu C., Pfeilschifter J., Mundy G.R., and Roodman G.D. Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci USA 85 (1988) 5683-5687
9. Geiser A.G., Zeng Q.Q., Sato M., Helvering L.M., Hirano T., and Turner C.H. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta 1 gene. Bone 23 (1998) 87-93
10. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D., Boyle W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15 (2000) 2-12
11. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998) 610-615
12. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 (1998) 3597-3602
13. Mezquita-Raya P., de la Higuera M., García D.F., et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 16 (2005) 1368-1374
14. Rogers A., Saleh G., Hannon R.A., Greenfield D., and Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87 (2002) 4470-4475
15. Thomas T. Leptin and fragility fracture: evidence for a protective effect in humans. Am J Med 117 (2004) 966-968
16. Ducy P., Amling M., Takeda S., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
17. Cock T.A., and Auwerx J. Leptin: cutting the fat off the bone. Lancet 362 (2003) 1572-1574
18. Fu L., Patel M.S., Bradley A., et al. The molecular clock mediates leptin-regulated bone formation. Cell 122 (2005) 803-815
19. Elefteriou F., Ahn J.D., Takeda S., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 (2005) 514-520
20. Pasco J.A., Henry M.J., Kotowicz M.A., et al. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86 (2001) 1884-1887
21. Yamauchi M., Sugimoto T., Yamaguchi T., et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 55 (2001) 341-347
22. Blain H., Vuillemin A., Guillemin F., et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87 (2002) 1030-1035
23. Weiss L.A., Barrett-Connor E., von Mühlen D., et al. Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo Study. J Bone Miner Res 21 (2006) 758-764
24. Schett G., Kiechl S., Bonora E., et al. Serum leptin level and the risk of nontraumatic fracture. Am J Med 117 (2004) 952-956
25. Roux C., Arabi A., Porcher R., et al. Serum leptin as a determinant of bone resorption in healthy postmenopausal women. Bone 33 (2003) 847-852
26. Thirunavukkarasu K., Miles R.R., Halladay D.L., et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-β (TGF-β). J Biol Chem 276 (2001) 36241-36250
27. Kiroyuki T., Kanematsu M., Yano K., et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 273 (1998) 27091-27096
28. Murakami T., Yamamoto M., Yamamoto M., et al. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252 (1998) 747-752
29. Karsdal M., Hjorth P., Henriksen K., et al. Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278 (2003) 44975-44987
30. Holloway W.R., Collier F.M., Aitken C.J., et al. Leptin inhibits osteoclast generation. J Bone Miner Res 17 (2002) 200-209
31. Wu X.Y., Wu X.P., Xie H., et al. Relationship between age-related reference values of serum osteoprotegerin and leptin in native Chinese women and compared with those in women of other races. Clin Chim Acta 389 (2008) 72-78
32. [No authors listed]. Obesity preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:1-253.
33. Assoian R.K., Komoriya A., Meyers C.A., Miller D.M., and Sporn M.B. Transforming growth factor-β in human platelets. J Biol Chem 258 (1983) 7155-7160
34. Kropf J., Schurek J.O., Wollner A., and Gressner A.M. Immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood; assay development and comparison. Clin Chem 43 (1997) 1965-1974
35. Toom A., Arend A., Gunnarsson D., et al. Bone formation zones in heterotopic ossification: histologic findings and increased expression of bone morphogenetic protein 2 and transforming growth factors β2 and β3. Calcif Tissue Int 80 (2007) 259-267
36. Karst M., Gorny G., Sells Galvin R.J., and Oursler M.J. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-β regulation of osteoclast differentiation. J Cell Physiol 200 (2004) 99-106
37. Yamada Y., Miyauchi A., Goto J., et al. Association of a polymorphism of the transforming growth factor-beta 1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13 (1998) 1569-1576
38. Grainger D.J., Heathcote K., Chiano M., et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 8 (1999) 93-97
39. Yamada Y., Miyauchi A., Tanakagi Y., et al. Association of a polymorphism of the transforming growth factor beta-1 gene with prevalent vertebral fractures in Japanese women. Am J Med 109 (2000) 244-247
40. Yamada Y., Ando F., Niino N., and Shimokata H. Transforming growth factor-beta 1 gene polymorphism and bone mineral density. JAMA 285 (2001) 167-168
41. Hinke V., Seck T., Clanget C., Scheidt-Nave C., Ziegler R., and Pfeilschifter J. Association of transforming growth factor-beta 1 (TGFbeta1) T29→C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta 1 in population-based sample of postmenopausal German women. Calcif Tissue Int 69 (2001) 315-320
42. 869→C polymorphism, of the transforming growth factor-β1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med 79 (2001) 149-156
43. Langdahl B.L., Carstens M., Stenkjaer L., and Eriksen E.F. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 32 (2003) 297-310
44. Dick I.M., Devine A., Li S., Dhaliwal S.S., and Prince R.L. The T869C TGF β polymorphism is associated with fracture, bone mineral density, and calcaneal quantitative ultrasound in elderly women. Bone 33 (2003) 335-341
45. Langdahl B.L., Uitterlinden A.G., Ralston S.H., et al. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone 42 (2008) 969-981
46. Bord S., Beavan S., Ireland D., Horner A., and Compston J.E. Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. Bone 29 (2001) 216-222
47. Shaarawy M., Zaki S., Sheiba M., and El-Minawi A.M. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta 2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis. Clin Lab 49 (2003) 625-636
48. Grainger D.J., Percival J., Chiano M., and Spector T.D. The role of serum TGF-β isoforms as potential markers of osteoporosis. Osteoporos Int 9 (1999) 398-404
49. Ivanović V., Demajo M., Krtolica K., et al. Elevated plasma TGF-β1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 371 (2006) 191-193
50. Li X., Yue Z.C., Zhang Y.Y., et al. Elevated serum level and gene polymorphisms of TGF-beta 1 in gastric cancer. J Clin Lab Anal 22 (2008) 164-171
51. Vejchapipat P., Theamboonlers A., Poomsawat S., Chittmittrapap S., and Poovorawan Y. Serum transforming growth factor-beta 1 and epidermal growth factor in biliary atresia. Eur J Pediatr Surg (2008) [Electronic publication ahead of print]
52. Dehaghani A.S., Rad N.R., Fattahi M.J., et al. Investigation of soluble HER2 and transforming growth factor beta-1 serum levels in gestational trophoblastic disease. Pathol Oncol Res (2008) [Electronic publication ahead of print]
53. Fain J.N., Tichansky D.S., and Madan A.K. Transforming growth factor β1 release by human adipose tissue is enhanced in obesity. Metabolism 54 (2005) 1546-1551
54. Porreca E., Di Febbo C., Vitacolonna E., et al. Transforming growth factor-beta 1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 15 (2002) 759-765
55. Kudlacek S., Schneider B., Woloszczuk W., et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32 (2003) 681-686
56. Mu L., Katsaros D., Lu L., et al. TGF-beta 1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br J Cancer 99 (2008) 1357-1363